Wohl D, et al. Patient-reported outcomes among HIV-1-infected adults randomized to B/F/TAF versus DTG/ABC/3TC in two Phase 3 controlled clinical trials over 48 weeks. AIDS 2018.
AQ-13 veelbelovend medicijn tegen resistente ‘Plasmodium falciparum’
sep 2017 | Parasitaire infecties